Zydus receives very last nod from USFDA for Estradiol Transdermal System

Zydus receives very last nod from USFDA for Estradiol Transdermal System

by admin- Friday, December 2nd, 2022 03:23:42 PM

Zydus Lifesciences acquired final approval from the United States Food and Drug Administration (USFDA) to marketplace Estradiol Transdermal System USP, 0.0.5 mg/day, zero.0375 mg/day, 0.05 mg/day, 0.1/2 mg/day, and 0.1 mg/day.

Estradiol Transdermal System is indicated to treat slight to extreme signs and symptoms of menopause which incorporates feelings of heat in the face, neck and chest or unexpected robust emotions of warmth, hot flushes and vaginal dryness in women. The drug might be manufactured at the organization’s method production facility at Moraiya, Ahmedabad, India.

News Updates